valganciclovir
Selected indexed studies
- Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. (JAMA, 2023) [PMID:37279999]
- A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. (J Am Soc Nephrol, 2023) [PMID:36749127]
- Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. (Am J Transplant, 2007) [PMID:17640310]
_Worker-drafted node — pending editorial review._
Connections
valganciclovir is a side effect of
Sources
- Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. (2023) pubmed
- A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. (2023) pubmed
- Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. (2007) pubmed
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir. (2024) pubmed
- Valganciclovir in Infants with Hearing Loss and Clinically Inapparent Congenital Cytomegalovirus Infection: A Nonrandomized Controlled Trial. (2024) pubmed
- Valganciclovir: recent progress. (2010) pubmed
- Valganciclovir and Risk for Neutropenia: When the Friend Becomes the Foe. (2024) pubmed
- Valganciclovir. (2001) pubmed
- Optimizing valganciclovir dosing strategies: a comprehensive review. (2026) pubmed
- Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. (2024) pubmed